The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Species- and cell type-specific requirements for cellular transformation
Open accessAbstract
Recent evidence suggests that human cells require more genetic changes for neoplastic transformation than do their murine counterparts. However, a precise enumeration of these differences has never been undertaken. We have determined that perturbation of two signaling pathways-involving p53 and Raf-suffices for the tumorigenic conversion of normal murine fibroblasts, while perturbation of six pathways-involving p53, pRb, PP2A, telomerase, Raf, and Ral-GEFs-is needed for human fibroblasts. Cell type-specific differences also exist in the requirements for tumorigenic transformation: immortalized human fibroblasts require the activation of Raf and Ral-GEFs, human embryonic kidney cells require the activation of PI3K and Ral-GEFs, and human mammary epithelial cells require the activation of Raf, PI3K, and Ral-GEFs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Self-citationThe serial cultivation of human diploid cell strains
Hayflick, L., & Moorhead, P. S. (1961) · Experimental Cell Research · doi:10.1016/0014-4827(61)90192-6 · Cited by 8,508 · cited 1×
“In contrast, and also consistent with compare the requirements of primary hFS fibroblasts expressing previous observations (Hayflick and Moorhead, 1961), hFS fi- ectopic hTERT and primary mNBS fibroblasts to escape Rasbroblasts proceeded to proliferate until passage 53 (P53), when induced…”
ResultOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 3×
“Like WT-MEFs (Serrano et al., 1997), primary mNBS fibro- tion of the ras oncogene, whereas LT-WT-expressing cells escaped (Figure 2B).”
BackgroundMethodras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Todaro, G. J., & Green, H. (1963) · The Journal of Cell Biology · doi:10.1083/jcb.17.2.299 · Cited by 2,736
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
Self-citationJanssens, V., & Goris, J. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3530417 · Cited by 1,902
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690 · cited 2×
“, 1997) and EcoR1 fragment of Ral-N28 (described in Urano han and Weinberg, 2000; Sherr and McCormick, 2002).”
MethodTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Cited by
Capturing complex 3D tissue physiology in vitro
Griffith, L. G., & Swartz, M. A. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1858 · Cited by 2,290
Intra-tumour heterogeneity: a looking glass for cancer?
Marusyk, A., Almendro, V., & Polyak, K. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3261 · Cited by 2,000
Modeling Tissue Morphogenesis and Cancer in 3D
Yamada, K. M., & Cukierman, E. (2007) · Cell · doi:10.1016/j.cell.2007.08.006 · Cited by 1,751
Genetics and biology of pancreatic ductal adenocarcinoma
Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,577
Regulation of the INK4b–ARF–INK4a tumour suppressor locus: all for one or one for all
Gil, J., & Peters, G. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1987 · Cited by 843
“As alluded to above, this has echoes in the more prominent role of Arf in mouse cell senescence and might reflect differences in the operation of the signalling pathways in the two specie”
BackgroundPhosphatase‐mediated crosstalk between MAPK signaling pathways in the regulation of cell survival
Junttila, M. R., Li, S., & Westermarck, J. (2008) · The FASEB Journal · doi:10.1096/fj.06-7859rev · Cited by 826
High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat
Tian, X., Azpurua, J., Hine, C., Vaidya, A., Myakishev-Rempel, M., Ablaeva, J., Mao, Z., Nevo, E., Gorbunova, V., & Seluanov, A. (2013) · Nature · doi:10.1038/nature12234 · Cited by 784
RAS Interaction with PI3K: More Than Just Another Effector Pathway
Castellano, E., & Downward, J. (2011) · Genes & Cancer · doi:10.1177/1947601911408079 · Cited by 762
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677
Modelling breast cancer: one size does not fit all
Vargo-Gogola, T., & Rosen, J. M. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2193 · Cited by 679
Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene
Boehm, J. S., Zhao, J. J., Yao, J., Kim, S. Y., Firestein, R., Dunn, I. F., Sjostrom, S. K., Garraway, L. A., Weremowicz, S., Richardson, A. L., et al. (2007) · Cell · doi:10.1016/j.cell.2007.03.052 · Cited by 617
Role of chemokines in tumor growth
Raman, D., Baugher, P. J., Thu, Y. M., & Richmond, A. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.05.013 · Cited by 578
Bardeesy, N., Aguirre, A. J., Chu, G. C., Cheng, K.-H., Lopez, L. V., Hezel, A. F., Feng, B., Brennan, C., Weissleder, R., Mahmood, U., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601273103 · Cited by 581
Miura, M., Miura, Y., Padilla-Nash, H. M., Molinolo, A. A., Fu, B., Patel, V., Seo, B.-M., Sonoyama, W., Zheng, J. J., Baker, C. C., et al. (2006) · Stem Cells · doi:10.1634/stemcells.2005-0403 · Cited by 567
Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis
Sarkisian, C. J., Keister, B. A., Stairs, D. B., Boxer, R. B., Moody, S. E., & Chodosh, L. A. (2007) · Nature Cell Biology · doi:10.1038/ncb1567 · Cited by 490
A Genetic Screen for Candidate Tumor Suppressors Identifies REST
Westbrook, T. F., Martin, E. S., Schlabach, M. R., Leng, Y., Liang, A. C., Feng, B., Zhao, J. J., Roberts, T. M., Mandel, G., Hannon, G. J., et al. (2005) · Cell · doi:10.1016/j.cell.2005.03.033 · Cited by 489
Ras oncogenes and their downstream targets
Rajalingam, K., Schreck, R., Rapp, U. R., & Albert, Š. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.01.012 · Cited by 458
The Tumorigenicity of Human Embryonic Stem Cells
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)00005-5 · Cited by 451
Cancer in xeroderma pigmentosum and related disorders of DNA repair
Cleaver, J. E. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1652 · Cited by 427
Cancer-specific mutations in PIK3CA are oncogenic in vivo
Bader, A. G., Kang, S., & Vogt, P. K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510857103 · Cited by 420
Peto's Paradox: evolution's prescription for cancer prevention
Caulin, A. F., & Maley, C. C. (2011) · Trends in Ecology & Evolution · doi:10.1016/j.tree.2011.01.002 · Cited by 384
Hypersensitivity to contact inhibition provides a clue to cancer resistance of naked mole-rat
Seluanov, A., Hine, C., Azpurua, J., Feigenson, M., Bozzella, M., Mao, Z., Catania, K. C., & Gorbunova, V. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905252106 · Cited by 381
Chien, Y., Kim, S., Bumeister, R., Loo, Y.-M., Kwon, S. W., Johnson, C. L., Balakireva, M. G., Romeo, Y., Kopelovich, L., Gale, M., et al. (2006) · Cell · doi:10.1016/j.cell.2006.08.034 · Cited by 368
Activation of RalA is critical for Ras-induced tumorigenesis of human cells
Lim, K.-H., Baines, A. T., Fiordalisi, J. J., Shipitsin, M., Feig, L. A., Cox, A. D., Der, C. J., & Counter, C. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.030 · Cited by 355
“Impeding RalGEF function via the expression of a dominant-negative version of its substrate also diminished Ras-mediated transformation of the same human cells (Hamad et al., 2002; Rangarajan et al., 2004).”
BackgroundMultiple pathways regulated by the tumor suppressor PP2A in transformation
Westermarck, J., & Hahn, W. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.001 · Cited by 344
p53-Mediated Hematopoietic Stem and Progenitor Cell Competition
Bondar, T., & Medzhitov, R. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.03.002 · Cited by 342
“Multiple steps of acquisition of mutations in tumor suppressors and oncogenes, each followed by clonal expansion, is a widely accepted model of tumorigenesis, which is thought to explain how rare and independent mutations can accumulate in a single clone (Rangarajan et al., 2004).”
Mechanisms of cancer resistance in long-lived mammals
Seluanov, A., Gladyshev, V. N., Vijg, J., & Gorbunova, V. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0004-9 · Cited by 323
Transformation of Different Human Breast Epithelial Cell Types Leads to Distinct Tumor Phenotypes
Ince, T. A., Richardson, A. L., Bell, G. W., Saitoh, M., Godar, S., Karnoub, A. E., Iglehart, J. D., & Weinberg, R. A. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.06.013 · Cited by 309
Self-citation3D Bioprinting of Tissue/Organ Models
Pati, F., Gantelius, J., & Svahn, H. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201505062 · Cited by 301
Bmi1 Controls Tumor Development in an Ink4a/Arf-Independent Manner in a Mouse Model for Glioma
Bruggeman, S. W. M., Hulsman, D., Tanger, E., Buckle, T., Blom, M., Zevenhoven, J., van Tellingen, O., & van Lohuizen, M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.032 · Cited by 292
Milyavsky, M., Gan, O. I., Trottier, M., Komosa, M., Tabach, O., Notta, F., Lechman, E., Hermans, K. G., Eppert, K., Konovalova, Z., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.05.016 · Cited by 287
Carnero, A. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210789941865 · Cited by 272
Funes, J. M., Quintero, M., Henderson, S., Martinez, D., Qureshi, U., Westwood, C., Clements, M. O., Bourboulia, D., Pedley, R. B., Moncada, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700690104 · Cited by 256
Modelling tissues in 3D: the next future of pharmaco-toxicology and food research?
Mazzoleni, G., Di Lorenzo, D., & Steimberg, N. (2009) · Genes & Nutrition · doi:10.1007/s12263-008-0107-0 · Cited by 253
Divergent Roles for RalA and RalB in Malignant Growth of Human Pancreatic Carcinoma Cells
Lim, K.-H., O'Hayer, K., Adam, S. J., Kendall, S. D., Campbell, P. M., Der, C. J., & Counter, C. M. (2006) · Current Biology · doi:10.1016/j.cub.2006.10.023 · Cited by 250
Wu, B., & Guo, W. (2015) · Journal of Cell Science · doi:10.1242/jcs.156398 · Cited by 240
Genetically engineered pigs as models for human disease
Perleberg, C., Kind, A., & Schnieke, A. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.030783 · Cited by 222
CIP2A Is Associated with Human Breast Cancer Aggressivity
Côme, C., Laine, A., Chanrion, M., Edgren, H., Mattila, E., Liu, X., Jonkers, J., Ivaska, J., Isola, J., Darbon, J.-M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3283 · Cited by 221
Invasive three-dimensional organotypic neoplasia from multiple normal human epithelia
Ridky, T. W., Chow, J. M., Wong, D. J., & Khavari, P. A. (2010) · Nature Medicine · doi:10.1038/nm.2265 · Cited by 217
“Genetically engineered mice are costly, time-consuming, not amenable to high-throughput combinatorial genetic or pharmacological screens and can show considerable differences from humans with regard to requirements for oncogenic transformatio”
CPEB and two poly(A) polymerases control miR-122 stability and p53 mRNA translation
Burns, D. M., D’Ambrogio, A., Nottrott, S., & Richter, J. D. (2011) · Nature · doi:10.1038/nature09908 · Cited by 193
Requirement of the NF-κB Subunit p65/RelA for K-Ras–Induced Lung Tumorigenesis
Bassères, D. S., Ebbs, A., Levantini, E., & Baldwin, A. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4290 · Cited by 189
Lim, K.-H., & Counter, C. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.014 · Cited by 159
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1093 · Cited by 149
“In full accordance with a requirement of PP2A inhibition for cellular transformation by activated RAS (6, 7), PP2A inhibition promotes malignant growth of various cell types with RAS activating mutations (15, 17).”
BackgroundC-Raf Is Required for the Initiation of Lung Cancer by K-RasG12D
Karreth, F. A., Frese, K. K., DeNicola, G. M., Baccarini, M., & Tuveson, D. A. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-10-0044 · Cited by 149
RalA and RalB: Antagonistic Relatives in Cancer Cell Migration
Oxford, G., Owens, C. R., Titus, B. J., Foreman, T. L., Herlevsen, M. C., Smith, S. C., & Theodorescu, D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1957 · Cited by 139
Bioengineering approaches to guide stem cell-based organogenesis
Gjorevski, N., Ranga, A., & Lutolf, M. P. (2014) · Development · doi:10.1242/dev.101048 · Cited by 137
“Furthermore, although knowledge obtained from animal models adequately describes a large part of organogenesis in humans, numerous aspects of human development and disease are unique to our species (Hansen et al., 2010; Rangarajan et al., 2004).”
BackgroundCPEB regulation of human cellular senescence, energy metabolism, and p53 mRNA translation
Burns, D. M., & Richter, J. D. (2008) · Genes & Development · doi:10.1101/gad.1697808 · Cited by 134
Mammary epithelial cell transformation: Insights from cell culture and mouse models
Dimri, G., Band, H., & Band, V. (2005) · Breast Cancer Research · doi:10.1186/bcr1275 · Cited by 120
Immortalizing Cells for Human Consumption
Soice, E., & Johnston, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111660 · Cited by 119
Cipriano, R., Kan, C. E., Graham, J., Danielpour, D., Stampfer, M., & Jackson, M. W. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015022108 · Cited by 92
IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways
Benatar, T., Yang, W., Amemiya, Y., Evdokimova, V., Kahn, H., Holloway, C., & Seth, A. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1816-4 · Cited by 89
“Mutations in RAS family members promote both proliferation and tumorigenesis in mammalian cells and occur in approximately 30% of human cancers [28–31].”
BackgroundReuter, J. A., Ortiz-Urda, S., Kretz, M., Garcia, J., Scholl, F. A., Pasmooij, A. M. G., Cassarino, D., Chang, H. Y., & Khavari, P. A. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.002 · Cited by 88
Niemelä, M., Kauko, O., Sihto, H., Mpindi, J.-P., Nicorici, D., Pernilä, P., Kallioniemi, O.-P., Joensuu, H., Hautaniemi, S., & Westermarck, J. (2012) · Oncogene · doi:10.1038/onc.2011.599 · Cited by 79
Toward the broad adoption of 3D tumor models in the cancer drug pipeline
Cox, M. C., Reese, L. M., Bickford, L. R., & Verbridge, S. S. (2015) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5b00172 · Cited by 80
Ral GTPases: crucial mediators of exocytosis and tumourigenesis
Shirakawa, R., & Horiuchi, H. (2015) · Journal of Biochemistry · doi:10.1093/jb/mvv029 · Cited by 76
Kauko, O., Imanishi, S. Y., Kulesskiy, E., Yetukuri, L., Laajala, T. D., Sharma, M., Pavic, K., Aakula, A., Rupp, C., Jumppanen, M., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011265 · Cited by 65
McCloskey, C. W., Goldberg, R. L., Carter, L. E., Gamwell, L. F., Al-Hujaily, E. M., Collins, O., Macdonald, E. A., Garson, K., Daneshmand, M., Carmona, E., et al. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00053 · Cited by 67
“Furthermore, it has been shown that murine cells require fewer genetic alterations than human cells to undergo transformation, again making it difficult to draw conclusions on the origin of cancer in humans from transgenic murine models (11, 12) For this reason, spontaneous models of EOC would be helpful to better und…”
BackgroundKauko, O., Laajala, T. D., Jumppanen, M., Hintsanen, P., Suni, V., Haapaniemi, P., Corthals, G., Aittokallio, T., Westermarck, J., & Imanishi, S. Y. (2015) · Scientific Reports · doi:10.1038/srep13099 · Cited by 61
Evidence for improved DNA repair in the long-lived bowhead whale
Firsanov, D., Zacher, M., Tian, X., Sformo, T. L., Zhao, Y., Tombline, G., Lu, J. Y., Zheng, Z., Perelli, L., Gurreri, E., et al. (2025) · Nature · doi:10.1038/s41586-025-09694-5 · Cited by 61
Wojtowicz, E. E., Lechman, E. R., Hermans, K. G., Schoof, E. M., Wienholds, E., Isserlin, R., van Veelen, P. A., Broekhuis, M. J. C., Janssen, G. M. C., Trotman-Grant, A., et al. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.06.008 · Cited by 60
“…was never observed in human xenografts through three serial transplantations (30 weeks total), suggesting that the inherent susceptibility of murine cells to oncogenic transformation may contribute to the development of (pre-) malignancy (Balmain and Harris, 2000; Rangarajan et al., 2004).”
Laine, A., Nagelli, S. G., Farrington, C., Butt, U., Cvrljevic, A. N., Vainonen, J. P., Feringa, F. M., Grönroos, T. J., Gautam, P., Khan, S., et al. (2020) · doi:10.1101/2020.08.27.269902 · Cited by 54
Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors
O’Connor, C. M., Leonard, D., Wiredja, D., Avelar, R. A., Wang, Z., Schlatzer, D., Bryson, B., Tokala, E., Taylor, S. E., Upadhyay, A., et al. (2020) · Oncogene · doi:10.1038/s41388-019-1012-2 · Cited by 48
Fenwick, R. B., Prasannan, S., Campbell, L. J., Nietlispach, D., Evetts, K. A., Camonis, J., Mott, H. R., & Owen, D. (2009) · Biochemistry · doi:10.1021/bi802129d · Cited by 47
Liu, N., He, Q.-M., Chen, J.-W., Li, Y.-Q., Xu, Y.-F., Ren, X.-Y., Sun, Y., Mai, H.-Q., Shao, J.-Y., Jia, W.-H., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-111 · Cited by 26
Welman, A., Cawthome, C., Ponce-Perez, L., Barraclough, J., Danson, S., Murray, S., Cummings, J., Allen, T. D., & Dive, C. (2006) · Neoplasia · doi:10.1593/neo.06475 · Cited by 26
Metadata
- Authors
- Rangarajan, A., Hong, S. J., Gifford, A., & Weinberg, R. A.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2004-08
- Volume
- 6
- Issue
- 2
- Pages
- 171-183
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2165928290
- Cited by
- 555
- References
- 41
- FWCI
- 14.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.